A citation-based method for searching scientific literature

Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina M Young, Jennifer L Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H June, Michael C Milone. J Clin Invest 2019
Times Cited: 304



Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin, Guangjun Jing, Wei Sang, Feng Zhu, Wei Chen, Qingyun Wu, Yao Yao, Gang Wang, Jing Zhao, Junnian Zheng, Zhenyu Li, Kailin Xu. Lancet Haematol 2019
Times Cited: 136




List of shared articles



Times cited


Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
Yang Liu, Wei Chen, Mingxiao Yu, Hujun Li, Hai Cheng, Jiang Cao, Zhiling Yan, Ming Shi, Feng Zhu, Haiying Sun,[...]. Transplant Cell Ther 2022
0

Resistance and recurrence of malignancies after CAR-T cell therapy.
Wanying Zeng, Pumin Zhang. Exp Cell Res 2022
0

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta. Biomark Res 2022
0

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. BMC Cancer 2022
0

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.
Huan Zhang, Man Liu, Xia Xiao, Hairong Lv, Yanyu Jiang, Xin Li, Ting Yuan, Mingfeng Zhao. Leuk Lymphoma 2022
2

Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.
Raphaëlle Toledano Zur, Galit Adler, Katerina Shamalov, Yair Tal, Chen Ankri, Cyrille J Cohen. Exp Suppl 2022
0

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu,[...]. J Clin Oncol 2022
2

CAR T cell therapy for multiple myeloma: What have we learned?
Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen. Leukemia 2022
1



Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
Xue Wang, Lina Zhao, Jing Wang, Yue Yao, Jiaojiao Wang, Shengwei Ji, Tian Hua, Shiyuan Wang, Hai Cheng, Ming Shi,[...]. Front Immunol 2022
0


Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Binod Dhakal, Parameswaran N Hari, Saad Z Usmani, Mehdi Hamadani. Bone Marrow Transplant 2021
8

CAR T cell therapies for patients with multiple myeloma.
Lekha Mikkilineni, James N Kochenderfer. Nat Rev Clin Oncol 2021
60

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki. Mol Ther 2021
12

Conventional T cell therapies pave the way for novel Treg therapeutics.
Lucy Z Li, Zheng Zhang, Vijay G Bhoj. Cell Immunol 2021
2

Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao,[...]. Cancer Med 2021
13

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.
Ghulam Rehman Mohyuddin, Anthony Rooney, Nicole Balmaceda, Muhammad Aziz, Douglas W Sborov, Brian McClune, Shaji K Kumar. Blood Adv 2021
11

Immunogenicity of CAR T cells in cancer therapy.
Dimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher, Nabil Ahmed, Mohamad Hamieh, Meenakshi Hegde, Marco Ruella, Barbara Savoldo, Nirali N Shah, Cameron J Turtle,[...]. Nat Rev Clin Oncol 2021
33


Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Qin Yang, Xin Li, Fangrong Zhang, Qiaohui Yang, Wen Zhou, Jing Liu. Int J Med Sci 2021
2

Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Faroogh Marofi, Safa Tahmasebi, Heshu Sulaiman Rahman, Denis Kaigorodov, Alexander Markov, Alexei Valerievich Yumashev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Rebar N Mohammed,[...]. Stem Cell Res Ther 2021
5